Therapy Areas: AIDS & HIV
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
14 July 2025 - HIV medication company Gilead Sciences Inc (Nasdaq: GILD) reported on Monday that it has presented new data at IAS 2025 from its Phase 3 PURPOSE trials, confirming the efficacy and tole...
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
14 July 2025 - Biopharmaceutical company Merck & Co, Inc (NYSE: MRK), known as MSD outside the US and Canada, announced on Monday that it will initiate Phase 3 clinical trials for MK-8527, an inve...
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement
20 June 2025 - Immuno Cure BioTech, a clinical-stage biotechnology group based in Hong Kong Science Park, announced on Thursday its upcoming collaboration with US-based PharmaJet to evaluate the safet...
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
29 May 2025 - Clinical stage biopharmaceutical company Estrella Immunopharma Inc (NASDAQ:ESLA) reported on Thursday that the first patient has been dosed in the second cohort of its Phase I/II STARLIG...
bioMérieux receives CE-marking for LUMED APSS to support antimicrobial stewardship in Europe
7 April 2025 - French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Monday that it has obtained CE-marking for LUMED APSS, a clinical decision support system designed to enha...
Langhua Pharmaceutical passes US FDA's on-site inspection
31 March 2025 - Viva Biotech Holdings announced on Friday that its wholly-owned subsidiary, Zhejiang Langhua Pharmaceutical Co., Ltd., successfully completed a cGMP on-site inspection by the US Food a...